Patents by Inventor Gerald R. Nakamura

Gerald R. Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-INFLUENZA B VIRUS HEMAGGLUTININ ANTIBODIES AND METHODS OF USE
    Publication number: 20150274812
    Abstract: The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: March 26, 2015
    Publication date: October 1, 2015
    Applicant: GENENTECH, INC.
    Inventors: Lee Swem, Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Gerald R. Nakamura, Hyunjoo Park
  • ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE
    Publication number: 20150259400
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: May 29, 2015
    Publication date: September 17, 2015
    Applicant: GENENTECH, INC.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swem
  • Anti-hemagglutinin antibodies and methods of use
    Patent number: 9067979
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: June 30, 2015
    Assignee: Genentech, Inc.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swern
  • ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE
    Publication number: 20140248286
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicant: Genentech, Inc.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swem
  • ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE
    Publication number: 20140161822
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: November 12, 2013
    Publication date: June 12, 2014
    Applicant: Genentech, Inc.
    Inventors: Min XU, Mercedesz BALAZS, Ning CHAI, Nancy Chiang, Henry CHIU, Zhaoyu JIN, Zhonghua LIN, Patrick LUPARDUS, Gerald R. NAKAMURA, Hyunjoo PARK, Lee SWEM
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20140154242
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: September 17, 2013
    Publication date: June 5, 2014
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • Immunoglobulin variants and uses thereof
    Patent number: 8562992
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: October 22, 2013
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • ASSAYS FOR DETECTING ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE IN ANAPHYLAXIS
    Publication number: 20110183363
    Abstract: The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.
    Type: Application
    Filed: October 26, 2010
    Publication date: July 28, 2011
    Inventors: Saloumeh Fischer, Dana L. Baker, Henry B. Lowman, Gerald R. Nakamura
  • POLYPEPTIDES THAT BIND BR3 AND USES THEREOF
    Publication number: 20100280227
    Abstract: The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.
    Type: Application
    Filed: July 13, 2010
    Publication date: November 4, 2010
    Applicant: GENENTECH, INC.
    Inventors: CHRISTINE M. AMBROSE, MERCEDESZ BALAZS, LAURA DEFORGE, MARK S. DENNIS, GERMAINE FUH, STEPHEN D. HURST, CHINGWEI V. LEE, HENRY B. LOWMAN, FLAVIUS MARTIN, GERALD R. NAKAMURA, DHAYA SESHASAYEE, MELISSA A. STAROVASNIK, JEFFREY S. THOMPSON
  • Immunoglobulin variants and uses thereof
    Patent number: 7799900
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: September 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20090155257
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: October 22, 2008
    Publication date: June 18, 2009
    Applicant: GENENTECH, INC.
    Inventors: CAMELLIA W. ADAMS, ANDREW C. CHAN, CRAIG W. CROWLEY, HENRY B. LOWMAN, GERALD R. NAKAMURA, LEONARD G. PRESTA
  • Polypeptides That Bind Br3 and Uses Thereof
    Publication number: 20080181888
    Abstract: The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.
    Type: Application
    Filed: December 23, 2005
    Publication date: July 31, 2008
    Inventors: Christine M. Ambrose, Mercedesz Balazs, Laura DeForge, Mark S. Dennis, Germaine Fuh, Stephen D. Hurst, Chingwei V. Lee, Henry B. Lowman, Flavius Martin, Gerald R. Nakamura, Dhaya Seshasayee, Melissa Starovasnik, Jeffrey S. Thompson
  • IgE receptor antagonists
    Patent number: 7101851
    Abstract: The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated Fc?RI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides composition, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: September 5, 2006
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Gerald R. Nakamura, Mark E. Reynolds, Melissa A. Starovasnik
  • HIV envelopolype peptides
    Patent number: 6806055
    Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used.to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: October 19, 2004
    Assignee: Genentech, Inc.
    Inventors: Phillip W. Berman, Gerald R. Nakamura
  • HIV envelopolype peptides
    Publication number: 20040121317
    Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.
    Type: Application
    Filed: June 10, 2003
    Publication date: June 24, 2004
    Applicant: Genentech, Inc.
    Inventors: Phillip W. Berman, Gerald R. Nakamura
  • Ige receptor antagonists
    Publication number: 20040086942
    Abstract: The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated Fc&egr;RI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides compositions, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: March 20, 2003
    Publication date: May 6, 2004
    Inventors: Henry B Lowman, Gerald R Nakamura, Mark E Reynolds, Melissa A Starovasnik
  • HIV envelopolype peptides
    Publication number: 20030064361
    Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.
    Type: Application
    Filed: September 27, 2001
    Publication date: April 3, 2003
    Applicant: Genentech, Inc.
    Inventors: Phillip W. Berman, Gerald R. Nakamura
  • HIV envelope polypeptides
    Patent number: 6331404
    Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4-domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: December 18, 2001
    Assignee: Genentech, Inc.
    Inventors: Phillip W. Berman, Gerald R. Nakamura
  • HIV envelope polypeptides
    Patent number: 6042836
    Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: March 28, 2000
    Assignee: Genentech, Inc.
    Inventors: Phillip W. Berman, Gerald R. Nakamura
  • HIV envelope polypeptides
    Patent number: 5864027
    Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV as depicted in the figure. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3 and C4 domains of gp120 are determined. Also described are DNA sequences encoding gp120 from preferred vaccine strains of HIV.
    Type: Grant
    Filed: October 10, 1995
    Date of Patent: January 26, 1999
    Assignee: Genentech, Inc.
    Inventors: Phillip W. Berman, Gerald R. Nakamura